Aurobindo Pharma Ltd will acquire the remaining 49% stake in GLS Pharma Ltd for Rs 22.5 crore, making it a wholly-owned subsidiary. The acquisition of 5,90,361 equity shares is expected to be completed by December 31, 2024. GLS Pharma specializes in oncology products, including chemotherapy treatments.
